SYNLOGIC, INC. — Regulatory Filings 2016

Mar 29, 2016

8-K 1 a16-7453_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of the*

*Securities Exchange Act of 1934*

Date of Report (Date of earliest event reported): March 29, 2016

*Mirna Therapeutics, Inc.*

(Exact name of registrant as specified in its charter)

Delaware	001-37566	26-1824804
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

*2150 Woodward Street, Suite 100 Austin, TX 78744* (Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (512) 901-0900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\jms\C902026\16-7453-1\task7860982\7453-1-ba.htm',USER='C902026',CD='Mar 29 05:38 2016'

*Item 2.02 Results of Operations and Financial Condition.*

On March 29, 2016, Mirna Therapeutics, Inc. (“Mirna”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2015. The press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing of Mirna under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

*Item 9.01 Financial Statements and Exhibits.*

Exhibit No.	Description
99.1	Press release dated March 29, 2016.

2

SEQ.=1,FOLIO='2',FILE='C:\jms\C902026\16-7453-1\task7860982\7453-1-ba.htm',USER='C902026',CD='Mar 29 05:38 2016'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Alan Fuhrman
Alan Fuhrman
Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\jms\C902026\16-7453-1\task7860982\7453-1-ba.htm',USER='C902026',CD='Mar 29 05:38 2016'